Аннотация:
Despite the association of a worse HF-related clinical status with lower CoQ10 levels, the prognostic use of CoQ10 is controversial. The aim of this study is to optimize pharmacotherapy for patients with ischaemic CHF, based on the clinical and functional parameters of the heart and brain natriuretic peptide (BNP) plasma levels, which are correlated with the CoQ10 plasma levels, and to assess patient prognosis after receiving CoQ10 therapy. This prospective clinical study included 75 patients aged 56 to 63 years old with coronary heart disease (CHD) classified as class I–III according to the NYHA classification. After assessment of the clinical-instrumental characteristics of the CVD course (complaints, medical history, physical examination, a 6-minute walk test, echocardiography, and test for reactive hyperaemia), we determined the BNP level and CoQ10 plasma levels. At the same time, we assessed the efficacy of CoQ10 treatment (at a dose of 60 mg/per day) and tolerability in CVD-combi
Sizova Zh. M. Zhanna Mikhaylovna 1959-
Zakharova V. L. Valeriya Leonidovna 1971-
Alibejli K. A. k. Keklik Akhmedaga ky'zy' 1984-
Medvedev O. S.
Shikh E. V. Evgeniya Valeryevna 1962-
Bolevich S. Sergej 1964-
Bolevich S. S. Stefani Sergeevna 1989-
Vorobyev S. I.
Votrin S. V. Sergej Vladimirovich 1982-
Padalko V. V. Vladimir Vasilyevich 1943-
Novikov A. A.
Omarov I. A.
Сизова Ж. М. Жанна Михайловна 1959-
Захарова В. Л. Валерия Леонидовна 1971-
Алибейли К. А. к. Кеклик Ахмедага кызы 1984-
Медведев О. С.
Ших Е. В. Евгения Валерьевна 1962-
Болевич С. Сергей 1964-
Болевич С. С. Стефани Сергеевна 1989-
Воробьев С. И.
Вотрин С. В. Сергей Владимирович 1982-
Падалко В. В. Владимир Васильевич 1943-
Новиков А. А.
Омаров И. А.
Ubiquinone plasma levels are correlated with brain natriuretic peptide plasma levels in patients with chronic heart failure: The potential of coenzyme q10 combined therapy [Povezanost plazma nivoa ubihinona sa nivoem moždanog natriuretskog peptida kod pacijenata sa hronicnom bolešcu srca: Efekti kombinovane terapije koenzimom Q10]
Ubiquinone plasma levels are correlated with brain natriuretic peptide plasma levels in patients with chronic heart failure: The potential of...
Текст визуальный непосредственный
Serbian Journal of Experimental and Clinical Research
Vol.19, Issue2 P. 141-149
2018
Статья
Brain natriuretic peptide Chronic heart failure Coenzyme Q10-combined therapy
amino terminal pro brain natriuretic peptide angiotensin receptor antagonist antithrombocytic agent beta adrenergic receptor blocking agent brain natriuretic peptide dipeptidyl carboxypeptidase inhibitor diuretic agent hydroxymethylglutaryl coenzyme A reductase inhibitor nitric acid derivative ubidecarenone ubiquinone adult Article clinical feature controlled study disease association disease course disease duration drug efficacy drug tolerability echocardiography female follow up heart ejection fraction heart failure human hyperemia ischemic heart disease major clinical study male medical history New York Heart Association class outcome assessment physical examination prospective study protein analysis protein blood level six minute walk test supplementation
Despite the association of a worse HF-related clinical status with lower CoQ10 levels, the prognostic use of CoQ10 is controversial. The aim of this study is to optimize pharmacotherapy for patients with ischaemic CHF, based on the clinical and functional parameters of the heart and brain natriuretic peptide (BNP) plasma levels, which are correlated with the CoQ10 plasma levels, and to assess patient prognosis after receiving CoQ10 therapy. This prospective clinical study included 75 patients aged 56 to 63 years old with coronary heart disease (CHD) classified as class I–III according to the NYHA classification. After assessment of the clinical-instrumental characteristics of the CVD course (complaints, medical history, physical examination, a 6-minute walk test, echocardiography, and test for reactive hyperaemia), we determined the BNP level and CoQ10 plasma levels. At the same time, we assessed the efficacy of CoQ10 treatment (at a dose of 60 mg/per day) and tolerability in CVD-combi